A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
NCT ID: NCT05886478
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2024-02-08
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
No treatment will be provided during this study. Information already existing in the participants' medical charts will be reviewed and collected.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll approximately 50 participants.
This multi-center trial will be conducted in Europe. The participants are assessed after the last dose of BV for approximately 4 months and followed up for at least 12 months after the re-treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Brentuximab Vedotin
Participants with CTCL who were retreated with BV after relapse will be observed retrospectively and the outcomes will be observed from June 2023 to September 2023.
No intervention
As this is an observational study, no intervention will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
As this is an observational study, no intervention will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant who was treated with BV in at least 2 lines of therapy, other treatments could have been administered in between
* Participant has received three or more cycles of BV in retreatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Saint Andre
Bordeaux, , France
Hopital Saint Louis
Paris, , France
CHU Roeun
Rouen, , France
Universitätsmedizin Göttingen
Göttingen, , Germany
Klinikum Ludwigshafen, Hautklinik
Ludwigshafen, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Ospedale Maggiore Policlinico
Milan, , Italy
AZ OSP Citta' Della Salute (Torino)
Torino, , Italy
Hospital Clinic, Barcelona
Barcelona, , Spain
ICO Hospitalet, Barcelona
Barcelona, , Spain
Hospital Son Espases
Palma, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Brentuximab-5020
Identifier Type: -
Identifier Source: org_study_id